Ardena signs agreement with Race Oncology Limited to manufacture RC220

We are pleased to share Race Oncology’s latest announcement highlighting the agreement with Ardena for the manufacturing of their flagship RC220 bisantrene formulation.

We are thrilled to join forces with Race Oncology and contribute to their groundbreaking work in advancing cancer therapies.

According to Race Oncology’s CEO and Managing Director, Damian Clarke-Bruce, “We are pleased to welcome Ardena as a manufacturing partner, adding to our existing contracted manufacturing capability. Ardena’s position in Europe ensures ease of access to RC220 product for our European clinical trials and adds a second source of FDA-compliant pharmaceutical grade product.”

We would like to express our gratitude to Race Oncology for choosing Ardena as their manufacturing partner. We are committed to delivering EU compliant supplies for their clinical studies in Europe, while also serving as a backup source for their US and Australian programs.

This partnership marks a significant milestone in our shared mission to advance precision oncology and improve patient outcomes.

For the full announcement, please click here